

錦見俊雄 業績

論文(英文)

- 1.Kawarabayashi T, Nishikimi T, Takeuchi K, Takeda T Pseudo-coarctation of the abdominal aorta associated with renovascular hypertension. Angiology 1985;36:215-8
- 2.Nishikimi T, Kohno M, Matsuura T, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T Effect of exercise on circulating atrial natriuretic polypeptide in valvular heart disease. Am J Cardiol 1986 ;58:1119-20
- 3.Nishikimi T, Kohno M, Matsuura T, Kanayama Y, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T Circulating atrial natriuretic polypeptide during exercise in patients with essential hypertension. J Hypertens Suppl 1986 ;4:S546-9
- 4.Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, Kawakita Y, Nishikimi T, Takeuchi K, Takeda T Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 1987 ;22:99-103
- 5.Yasuda M, Nishikimi T, Murai K, Oku H, Takeuchi K, Takeda T, Komatsu H Cardiac function of patients with essential hypertension during exercise and isoproterenol infusion. Jpn Circ J 1987 ;51:125-37
- 6.Nishikimi T, Ochi H, Hirota K, Ikuno Y, Oku H, Takeuchi K, Takeda T Primary pericardial mesothelioma detected by gallium-67 scintigraphy. J Nucl Med 1987 ;28:1210-2
- 7.Nishikimi T, Oku H, Hirota K, Murai K, Kawarabayashi T, Yoshiyama M, Akioka K, Teragaki M, Yasuda M, Takenuchi K, Takeda T. Right and left coronary artery to left ventricle fistula detected by color Doppler flow mapping. Am Heart J 1987 ;114:890-4
- 8.Akioka A, Kohno M, Nishikimi T, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T. Influence of nisoldipine on hemodynamics and atrial natriuretic polypeptide at exercise loading in hypertensive patients : Nisoldipine edited by P.G.Hugenholtz, J.Meyer, Springer-Vulag Berlin

Heiderberg 1987 ;159-164

- 9.Nishikimi T, Kohno M, Itagane H, Hirota K, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K,Takeda T Influence of exercise on plasma atrial natriuretic factor levels in patients with myocardial infarction. Am Heart J 1988 ;115:753-60
- 10.Yasuda M, Nishikimi T, Akioka K, Teragaki M, Oku H, Takeuchi K, Takeda T, Naka K, Okuda K,Ikuno Y Relationship between cardiac function and the sympathetic nervous system during exercise in patients with essential hypertension. Jpn Circ J 1988 ;52:1121-31
- 11.Kohno M, Yasunari K, Murakawa K, Yokokawa K, Akioka K, Teragaki M, Yasuda M, Nishikimi T, Oku H, Takeuchi K, Takeda T. Physiological significance of atrial natriuretic peptides in essential hypertension. Jpn Circ J 1988 ;52:1465-7
- 12.Murai K, Hirota K, Nishikimi T, Kawarabayashi T, Yoshiyama M,Yasuda M, Teragaki M, Akioka K, Oku H, Takeuchi K, Takeda T. Pheochromocytoma with electrocardiographic change mimicking angina pectoris and cyclic change in direct arterial pressure-a case report: Angiology 1991;42:157-161
- 13.Uchino K, Frohlich ED, Nishikimi T, Isshiki T, Kardon MB Spontaneously hypertensive rats demonstrate increased renal vascular alpha 1-adrenergic receptor responsiveness. Am J Physiol 1991 ;260:R889-93
- 14.Uchino K, Nishikimi T, Frohlich ED Alpha 1-adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. Am J Physiol 1991 ;261:R576-80
- 15.Nishikimi T, Uchino K, Frohlich ED Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats. Am J Physiol 1992 ;262:R198-203
- 16.Isshiki T, Nishikimi T, Uchino K, Kardon MB, Frohlich ED Diltiazem reduces glomerular pressure in spontaneously hypertensive rats. Cardiovasc Drugs Ther 1992 ;6:91-2
17. Uchino K, Nishikimi T, Frohlich ED. The role of circulating and therapeutic agents on the intrarenal circulation. Current Opinion Cardiology 1992,7:752-758

- 18.Nishikimi T, Frohlich ED Glomerular hemodynamics in aortocaval fistula rats: role of renin-angiotensin system. Am J Physiol 1993 ;264:R681-6
- 19.Omura T, Teragaki M, Tani T, Yamagishi H, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Akioka K, Takeuchi K, Takeda T. Estimation of infarct size using serum troponin T concentration in patients with acute myocardial infarction. Jpn Circ J 1993 ;57:1062-70
- 20.Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993 ;25:1369-80
- 21.Yoshiyama M, Miura K, Nishikimi T, Teragaki M, Todi I, Akioka K, Takeuchi K, Takeda T Role of nitric oxide in the vasodilatory responses to acetylcholine and bradykinin in perfused hearts. Jpn Circ J 1993 ;57:1159-63
- 22.Nishikimi T, Miura K, Minamino N, Takeuchi K, Takeda T Role of endogenous atrial natriuretic peptide on systemic and renal hemodynamics in heart failure rats. Am J Physiol 1994 ;267:H182-6
- 23.Nishikimi T, Kitamura K, Saito Y, Shimada K, Ishimitsu T, Takamiya M, Kangawa K, Matsuo H, Eto T, Omae T, Matsuoka H. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension 1994 ;24:600-4
- 24.Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994 ;94:2158-61
- 25.Numabe A, Nishikimi T, Komatsu K, Frohlich ED Intrarenal hemodynamics in low- and high-output cardiac failure in rats. Am J Med Sci 1994 ;308:331-7
- 26.Yamagishi H, Akioka K, Itagane H, Tani T, Ohmura T, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Teragaki M, Takeuchi K, Takeda T. Relationship between insufficient redistribution in exercise thallium-201 myocardial single-photon emission computed tomography and reverse

redistribution at rest. Jpn Circ J 1995 ;59:23-32

27.Shimada K, Nishikimi T, Kawarabayashi T, Takeuchi K, Takeda T Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. Jpn Heart J 1995 ;36:81-9

28.Omura T, Teragaki M, Takagi M, Tani T, Nishida Y, Yamagishi H, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Akioka K, Takeuchi K, Takeda T. Myocardial infarct size by serum troponin T and myosin light chain 1 concentration. Jpn Circ J 1995 ;59:154-9

29.Nishikimi T, Yamagishi H, Takeuchi K, Takeda T An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995 ;29:856-61

30.Nishikimi T, Tani T, Ohmura T, Yamagishi H, Yanagi S, Yoshiyama M, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T Angiotensin II type-1 receptor antagonist as well as angiotensin converting enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Jpn Circ J 1995 ;59:754-61

31.Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995 ;26:1424-31

32.Nishikimi T, Kawano Y, Saito Y, Matsuoka H Effect of long-term treatment with selective vasopressin V₁ and V₂ receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 1996 ;27:275-82

33.Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension 1996 ;27:319-23

34.Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuoka H, Omae T Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996 ;9:523-8

- 35.Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. *Hypertension* 1996 ;28:22-30
- 36.Nishikimi T, Matsuoka H, Ishikawa K, Yoshihara F, Kawano Y, Kitamura K, Saito Y, Kangawa K, Matsuo H, Omae T. Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. *Hypertens Res* 1996 ;19:97-101
- 37.Ishimitsu T, Nishikimi T, Matsuoka H, Kangawa K, Kitamura K, Minami J, Matsuo H, Eto T Behaviour of adrenomedullin during acute and chronic salt loading in normotensive and hypertensive subjects. *Clin Sci* 1996 ;91:293-8
- 38.Yoshitomi Y, Nishikimi T, Abe H, Nagata S, Kuramochi M, Matsuoka H, Omae T Left ventricular systolic and diastolic function and mass before and after antihypertensive treatment in patients with essential hypertension. *Hypertens Res* 1997 ;20:23-8
- 39.Nishikimi T, Morimoto A, Ishikawa K, Saito Y, Kangawa K, Matsuo H, Kitamura K, Takishita S, Matsuoka H Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. *Clin Exp Hypertens* 1997 ;19:503-18
- 40.Morimoto A, Nishikimi T, Takaki H, Okano Y, Matsuoka H, Takishita S, Kitamura K, Miyata A, Kangawa K, Matsuo H Effect of exercise on plasma adrenomedullin and natriuretic peptide levels in myocardial infarction. *Clin Exp Pharmacol Physiol* 1997 ;24:315-20
- 41.Yoshibayashi M, Kamiya T, Kitamura K, Saito Y, Kangawa K, Nishikimi T, Matsuoka H, Eto T, Matsuo H Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. *Am J Cardiol* 1997 ;79:1556-8
- 42.Sumimoto T, Nishikimi T, Mukai M, Matsuzaki K, Murakami E, Takishita S, Miyata A, Matsuo H, Kangawa K Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. *Hypertension* 1997 ;30:741-5

- 43.Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T The role of vasopressin in essential hypertension. Plasma levels and effects of the V₁ receptor antagonist OPC-21268 during different dietary sodium intakes. Am J Hypertens 1997 ;10:1240-4
- 44.Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 1997 ;30:1369-75
- 45.Nishikimi T, Nagata S, Sasaki T, Tomimoto S, Matsuoka H, Takishita S, Kitamura K, Miyata A, Matsuo H, Kangawa K Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart 1997 ;78:390-5
- 46.Nishikimi T Adrenomedullin in cardiovascular disease. Adv Pharmacol 1998;42:599-603
- 47.Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998 ;31:202-8
- 48.Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998 ;135:21-8
- 49.Miyao Y, Nishikimi T, Goto Y, Miyazaki S, Daikoku S, Morii I, Matsumoto T, Takishita S, Miyata A, Matsuo H, Kangawa K, Nonogi H Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998 ;79:39-44
- 50.Yoshitomi Y, Nishikimi T, Kojima S, Kuramochi M, Takishita S, Matsuoka H, Miyata A, Matsuo H, Kangawa K Plasma levels of adrenomedullin in patients with acute myocardial infarction. Clin Sci 1998 ;94:135-9
- 51.Ishimitsu T, Minami J, Nishikimi T, Kawano Y, Takishita S, Kangawa K, Matsuo H, Matsuoka H

Responses of natriuretic peptides to acute and chronic salt loading in normotensive and hypertensive subjects. Hypertens Res 1998 ;21:15-22

52.Yoshitomi Y, Nishikimi T, Kojima S, Kuramochi M, Takishita S, Kangawa K, Matsuo H
Plasma natriuretic peptides as indicators of left ventricular remodeling after myocardial infarction.
Int J Cardiol 1998 ;64:153-60

53.Nishikimi T, Hayashi Y, Iribu G, Takishita S, Kosakai Y, Minamino N, Miyata A, Matsuo H,
Kuro M, Kangawa K Increased plasma adrenomedullin concentrations during cardiac surgery.
Clin Sci 1998 ;94:585-90

54.Yoshihara F, Nishikimi T, Kosakai Y, Isobe F, Matsuoka H, Takishita S, Kawashima Y, Saito Y,
Matsuo H, Kangawa K Atrial natriuretic peptide secretion and body fluid balance after bilateral
atrial appendectomy by the maze procedure. J Thorac Cardiovasc Surg 1998 ;116:213-9

55.Nagaya N, Nishikimi T, Uematsu M, Kyotani S, Satoh T, Nakanishi N, Matsuo H, Kangawa K
Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or
without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998 ;136:297-301

56.Nishikimi T, Horio T, Yoshihara F, Nagaya N, Matsuo H, Kangawa K Effect of adrenomedullin
on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. Eur J Pharmacol
1998 ;353:337-44

57.Kario K, Nishikimi T, Yoshihara F, Takishita S, Yamaoka R, Matsuo T, Matuso H, Mitsuhashi T,
Shimada K, Kangawa K Plasma levels of natriuretic peptides and adrenomedullin in elderly
hypertensive patients: relationships to 24 h blood pressure. J Hypertens 1998 ;16:1253-9

58.Yoshihara F, Nishikimi T, Horio T, Yutani C, Takishita S, Matsuo H, Ohe T, Kangawa K
Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular
hypertrophy in rats administered monocrotaline. Eur J Pharmacol 1998 14;355:33-9

59.Horio T, Nishikimi T, Yoshihara F, Nagaya N, Matsuo H, Takishita S, Kangawa K Production
and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by
interleukin-1beta and tumor necrosis factor-alpha. Endocrinology 1998 ;139:4576-80

- 60.Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, Suyama K, Aihara N, Kamakura S, Kangawa K, Takamiya M, Shimomura K Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. *Circulation* 1998 ;98:2433-40
- 61.Kakishita M, Nishikimi T, Okano Y, Satoh T, Kyotani S, Nagaya N, Fukushima K, Nakanishi N, Takishita S, Miyata A, Kangawa K, Matsuo H, Kunieda T Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. *Clin Sci* 1999;96:33-39
- 62.Nagaya N, Goto Y, Nishikimi T, Uematsu M, Miyao Y, Kobayashi Y, Miyazaki S, Hamada S, Kuribayashi S, Takamiya M, Matsuo H, Kangawa K, Nonogi H Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. *Clin Sci* 1999 ;96:129-36
63. Nagaya N, Nishikimi T, Horio T, Yoshihara F, Kanazawa A, Matsuo H, Kangawa K Cardiovascular and renal effects of adrenomedullin in rats with heart failure. *Am J Physiol* 1999 ;276:R213-8
- 64.Nagaya N, Nishikimi T, Uematsu M, Yoshitomi Y, Miyao Y, Miyazaki S, Goto Y, Kojima S, Kuramochi M, Matsuo H, Kangawa K, Nonogi H Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. *Heart* 1999 ;81:483-7
- 65.Morimoto A, Nishikimi T, Yoshihara F, Horio T, Nagaya N, Matsuo H, Dohi K, Kangawa K Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. *Hypertension* 1999 ;33:1146-52
- 66.Yoshibayashi M, Kamiya T, Nishikimi T, Saito Y, Matsuo H, Kangawa K Elevated plasma levels of adrenomedullin in congenital cyanotic heart disease. *Clin Sci* 1999;96:543-7
67. Sasaki T, Noguchi T, Komamura K, Nishikimi T, Yoshikawa H, Miyatake K Differential roles of endothelin-1 in the development of secondary pulmonary hypertension in patients with left heart failure with or without acute exacerbation. *J Card Fail* 1999 ;5:38-45
68. Sasaki T, Kubo T, Komamura K, Nishikimi T Effects of long-term treatment with pimobendan

on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. *J Cardiol* 1999 ;33:317-25

69. Minegishi T, Nakamura M, Abe K, Tano M, Andoh A, Yoshida M, Takagi T, Nishikimi T, Kojima M, Kangawa K Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy and pre-eclampsia. *Mol Hum Reprod* 1999 ;5:767-70
70. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. *Eur J Pharmacol* 1999 ;382:1-9
71. Ishimitsu T, Minami J, Nishikimi T, Yoshida K, Tsukada H, Kangawa K, Matsuoka H. Changes in plasma adrenomedullin in physiological and pathological conditions in human subjects. *J Cardiovasc Pharmacol* 1999;34(Suppl.4): S47-S51
72. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. *Hypertension* 2000;35:19-24
73. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. *Circulation* 2000 ;101:498-503
74. Yoshihara F, Nishikimi T, Horio T, Yutani C, Nagaya N, Matsuo H, Ohe T, Kangawa K Ventricular adrenomedullin concentration is a sensitive biochemical marker for volume and pressure overload in rats. *Am J Physiol Heart Circ Physiol* 2000 ;278:H633-H642
75. Hosoya K, Takeda K, Nishikimi T, Ishimitsu T, Matsuoka H Force-length relationship in dogs as a measure of protective effect of imidapril on regional myocardial ischemia and reperfusion injury.
Eur J Pharmacol 2000 ;390:157-166
76. Yoshihara F, Nishikimi T, Sasako Y, Kobayashi J, Kosakai Y, Hattori R, Horio T, Kitamura S, Matsuo H, Ohe T, Kangawa K Preservation of the right atrial appendage improves reduced plasma

atrial natriuretic peptide levels after the maze procedure. J Thorac Cardiovasc Surg 2000 ;119:790-794

77. Nagaya N, Nishikimi T, Yoshihara F, Horio T, Morimoto A, Kangawa K Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol Regul Integr Comp Physiol 2000 ;278:R1019-R1026

78. Oya H, Nagaya N, Furuichi S, Nishikimi T, Ueno K, Nakanishi N, Yamagishi M, Kangawa K, Miyatake K. Comparison of intravenous adrenomedullin with atrial natriuretic peptide in patients with congestive heart failure. Am J Cardiol. 2000 ;86:94-98.

79. Hamanaka I, Saito Y, Nishikimi T, Magaribuchi T, Kamitani S, Kuwahara K, Ishikawa M, Miyamoto Y, Harada M, Ogawa E, Kajiyama N, Takahashi N, Izumi T, Shirakami G, Mori K, Inobe Y, Kishimoto I, Masuda I, Fukuda K, Nakao K. Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. Am J Physiol Heart Circ Physiol. 2000 ;279:H388-H396

80. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000 22;102:865-870

81. Nishikimi T, Matsuoka H, Shimada K, Matsuo H, Kangawa K. Production and clearance sites of two molecular forms of adrenomedullin in human plasma. Am J Hypertens. 2000 ;13:1032-4.

82. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T. Gene Transfer of Human Prostacyclin Synthase Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats. Circulation. 2000 ;102:2005-2010.

83. Minami J, Nishikimi T, Ishimitsu T, Makino Y, Kawano Y, Takishita S, Kangawa K, Matsuoka H. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides levels in obese patients with essential hypertension J Cardiovasc Pharmacol 36 (supple.2) S83-86, 2000

84. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Oya H, Kyotani S, Sakamaki F, Ueno K, Nakanishi N, Miyatake K, Kangawa K. Hemodynamic and hormonal effects of adrenomedullin in

patients with pulmonary hypertension. Heart 2000;84:653-658

85. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol. 2000 ;279:H3031-H3039.
86. Nishikimi T, Nagata S, Sasaki T, Yoshihara F, Nagaya N, Horio T, Matsuo H, Matsuoka H, Kangawa K. The active molecular form of plasma adrenomedullin is extracted in the pulmonary circulation in patients with mitral stenosis: possible role of adrenomedullin in pulmonary hypertension. Clin Sci. 2001 ;100:61-66.
87. Asakawa H, Nishikimi T, Suzuki T, Hara S, Tsubokou Y, Yagi H, Yabe A, Tsuchiya N, Horinaka S, Kangawa K, Matsuoka H. Elevation of two molecular forms of adrenomedullin in plasma and urine in patients with acute myocardial infarction treated with early coronary angioplasty. Clin Sci. 2001 ;100:117-126.
88. Yoshihara F, Nishikimi T, Okano I, Horio T, Matsuo H, Takishita S, Ohe T, Kangawa K. Alterations of intrarenal adrenomedullin and its receptor system in heart failure rats. Hypertension. 2001;37:216-222
89. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T, Saito M, Teranishi M, Nakamura M, Ohrui M, Kawano Y, Matsuo H, Ishimitsu T, Takishita S, Matsuoka H, Kangawa K. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 2001 ;19:765-73
- (90). Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. [Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension]. J Cardiol. 2001 ;37:110-1
90. Nishikimi T, Futo Y, Tamano K, Takahashi M, Suzuki T, Minami J, Honda T, Uetake S, Asakawa H, Kobayashi N, Horinaka S, Ishimitsu T, Matsuoka H. Plasma Brain Natriuretic Peptide Levels in Chronic Hemodialysis Patients: Influence of Coronary Artery Disease. Am J Kidney Dis 2001 37: 1201-1208.

91. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. *Atherosclerosis*. 2001;156:255-65.
92. Nishida K, Watanabe K, Echigo S, Mayumi M, Nishikimi T. Increased plasma adrenomedullin levels in Kawasaki disease with coronary artery involvement. *Am J Med* 2001; 111:165-166
93. Nishikimi T, Minami J, Tamano K, Takahashi M, Numabe A, Futoo Y, Honda T, Kobayashi M, Uetake S, Mori Y, Takada M, Machiyama A, Saito T, Matsuoka H. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: an ambulatory 48-hour blood pressure study. *Hyp Res* 2001;24:507-514 -27
94. Nishikimi T, Yoshihara F, Kanazawa A, Okano I, Horio T, Nagaya N, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Role of increased circulating and renal adrenomedullin in rats with malignant hypertension. *Am J Physiol Regul Integr Comp Physiol*. 2001;281:R2079-87.
95. Nishikimi T, Minami J, Yasu T, Suzuki T, Kangawa K, Matsuoka K. Two molecular forms of plasma adrenomedullin during tilt test in normal healthy subjects. *Peptides* 2001; 22: 1867-1872
96. Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobatashi J, Hattori R, Minatoya K, Bando K, Kosakai Y, Horio T, Suga S, Takishita S, Matsuoka H, Ikeda Y, Yutani C, Kitamura S, Matsuo H, Ohe T, Kangawa K. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation. -Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure - *J Am Coll Cardiol* 2002;39:288-294
97. Yoshihara F, Horio T, Nishikimi T, Matsuo H, Kangawa K. Possible involvement of oxidative stress in hypoxia-induced adrenomedullin secretion in cultured rat cardiomyocytes. *Eur J Pharmacol*. 2002;436:1-6.
98. Minami J, Yoshii M, Todoroki M, Nishikimi T, Ishimitsu T, Fukunaga T, Matsuoka H. Effects of alcohol restriction on ambulatory blood pressure, heart rate, and heart rate variability in Japanese

men

Am J Hypertens 2002;15:125-129

99. Nishikimi T, Shibasaki I, Iida H, Asakawa H, Matsushita Y, Mori H, Mochizuki Y, Okamura Y, Horinaka S, Kangawa K, Shimada K, Matsuoka H. Molecular forms of adrenomedullin in pericardial fluid and plasma in patients with ischaemic heart disease. Clin Sci. 2002 ;102:669-677.
100. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, Yoshihara F, Kangawa K, Matsuoka H. Renoprotective effect of chronic adrenomedullin Infusion in Dahl salt-sensitive rats. Hypertension. 2002 ;39:1077-1082
101. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension. 2002 ;40:107-13.
102. Minami J, Todoroki M, Yoshii M, Mita S, Nishikimi T, Ishimitsu T, Matsuoka H. Effects of smoking cessation or alcohol restriction on metabolic and fibrinolytic variables in Japanese men. Clin Sci. 2002 ;103:117-22.
103. Nishikimi T, Tadokoro K, Wang X, Mori Y, Asakawa H, Akimoto K, Yoshihara F, Horio T, Minamino N, Matsuoka H. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. Eur J Pharmacol. 2002 ;453:175-81.
104. Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, Kawano Y. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis. 2002 ;40:974-982.
105. Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. Regul Pept. 2002 ;109:107-13.
106. Minami J, Nishikimi T, Todoroki M, Kashiwakura C, Yagi H, Ono H, Horinaka S, Ishimitsu T, Kangawa K, Matsuoka H. Source of plasma adrenomedullin in patients with pheochromocytoma. Am J Hypertens. 2002 ;15:994-7

107. Kobayashi N, Horinaka S, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nishikimi T, Matsuoka H. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. *J Hypertens.* 2002 ;20:2475-85.
108. Makino I, Makino Y, Yoshihara F, Nishikimi T, Kawarabayashi T, Kangawa K, Shibata K. Decreased mature adrenomedullin levels in feto-maternal tissues of pregnant women with histologic chorioamnionitis. *Biochem Biophys Res Commun.* 2003 ;301:437-42.
109. Nishikmi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective Effect of Adrenomedullin in Heart Failure. *Hyp Res* 2003;26: S121-S127
110. Nagaya N, Miyatake K, Kyotani S, Nishikimi T, Nakanishi N, Kangawa K. Pulmonary vasodilator respomse to adrenomedullin in patients with pulmooonary hypertension. *Hyp Res* 2003;26: S141-S146
111. Nishikimi T, Tadokoto K, Mori Y, Wang X, Akimoto K, Yoshihara F, Minamino N, Kangawa K, Matsuoka H. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats *Hypertension* 2003 41: 512-518
112. Tadokoro K, Nishikimi T, Mori Y, Wang X, Akimoto K, Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. *Regul Pept.* 2003 ;112:71-8.
113. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic Peptide in cultured adult rat cardiac fibroblasts. *Endocrinology.* 2003 ;144:2279-84.
114. Wang X, Nishikimi T, Akimoto K, Tadokoro K, Mori Y, Minamino N. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. *J Hypertens* 2003; 21:1171-1181

115. Alexander MR, Knowles JW, Nishikimi T, Maeda N. Increased atherosclerosis and smooth muscle cell hypertrophy in natriuretic Peptide receptor a-/apolipoprotein e-/ mice. *Arterioscler Thromb Vasc Biol.* 2003;23:1077-1082.
116. Watanabe K, Nishikimi T, Takamuro M, Yasuda K, Ishikawa Y, Tanabe S, Yamada O, Nagaya N, Matsuoka H, Kangawa K, Echigo S. Two Molecular Forms of Adrenomedullin in Congenital Heart Disease. *Pediatr Cardiol.* 2003;24:559-565
117. Takahashi M, Nishikimi T, Tamano K, Hara S, Kobayashi T, Honda T, Uetake S, Mitobe R, Matsuoka H. Multiple left ventricular diverticula detected by second harmonic imaging. *Circ J.* 2003 ;67:972-4.
118. Nishikimi T, Yoshihara F, Horinaka S, Kobayashi N, Mori Y, Tadokoro K, Akimoto K, Minamino N, Kangawa K, Matsuoka H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. *Hypertension.* 2003 ;42:1034-41.
- 118'. Author's Reply-Diagnostic Process of Left Ventricular Diverticulum - Takahashi M, Nishikimi T, Matsuoka H. *Circ J.* 68:272-273
119. Nishikimi T, Mori Y, Ishimura K, Tadokoro K, Yagi H, Yabe A, Horinaka S, Matsuoka H. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. *Am J Med.* 2004 ;116:517-523.
120. Nishikimi T, Matsuoka H. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. *Circulation.* 2004 ;109:e325-6
121. Nishikimi T, Matsuoka H. Are plasma levels of atrial natriuretic peptide, N-terminal ProANP, and brain natriuretic peptide affected by the presence of coronary artery disease? *Circulation.* 2004 ;109:e331
122. Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide levels indicate the distance from decompensated heart failure. *Circulation.* 2004 ;109:e329-30

123. Nishikimi T, Asakawa H, Tadokoro K, Mori Y, Iida H, Shibasaki I, Matsushita Y, Mori H, Mochizuki Y, Kangawa K, Matsuoka H. Different secretion patterns of two molecular forms of cardiac adrenomedullin in pressure- and volume-overloaded human heart failure. *J Cardiac Failure*. 2004;10: 321-327
124. Minami J, Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide and N-terminal proatrial natriuretic peptide levels in obese patients: a cause or result of hypertension? *Circulation*. 2004;110:e76
125. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, Shimokawa H, Ono H, Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. *J Hypertens*. 2004;22:1787-96.
126. Nishikimi T, Wang X, Akimoto K, Tadokoro K, Mori Y, Ishikawa Y, Ishimura K, Yoshihara F, Minamino N, Kangawa K, Matsuoka H. Alteration of renal adrenomedullin and its receptor system in the severely hypertensive rat: effect of diuretic. *Regul Pept*. 2005 ;124:89-98.
127. Nishikimi T, Matsuoka H. Letters Regarding Article by Bibbons-Domingo et al, "B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease: Data From the Heart and Soul Study" *Circulation*. 2005;111:e15.
128. Yoshihara F, Nishikimi T, Okano I, Hino J, Horio T, Tokudome T, Suga SI, Matsuoka H, Kangawa K, Kawano Y. Upregulation of intracardiac adrenomedullin and its receptor system in rats with volume overload-induced cardiac hypertrophy. *Regul Pept*. 2005;127:239-244.
129. Yoshihara F, Suga SI, Yasui N, Horio T, Tokudome T, Nishikimi T, Kawano Y, Kangawa K. Chronic administration of adrenomedullin attenuates the hypertension and increases renal nitric oxide synthase in Dahl salt-sensitive rats. *Regul Pept*. 2005;128:7-13.
130. Nishikimi T, Tadokoro K, Akimoto K, Mori Y, Ishikawa Y, Ishimura K, Horio T, Kangawa K, Matsuoka H. Response of adrenomedullin system to cytokine stimulation in cardiac fibroblasts -Role of adrenomedullin as an antifibrotic factor- *Cardiovasc Res* 2005;66:94-103
131. Nishikimi T, Hagaman J, Takahashi N, Kim S, Matsuoka H, Smithies O, Maeda N.

Increased susceptibility to heart failure in mice lacking natriuretic peptide receptor-A gene
Cardiovasc Res. 2005;66:104-113

132. Nishikimi T and Matsuoka H. Adrenomedullin in hypertension. Current Hypertension Review 2005;1:169-181

133. Yasu T, Nishikimi T, Kobayashi N, Ikeda N, Ueba H, Nakamura T, Funayama H, Kubo N, Kawakami M, Matsuoka H, Kangawa K, Saito M. Up-regulated synthesis of mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction. Regul Pept. 2005 ;129:161-6.

134. Nishikimi T and Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:231-42.

135. Ishimura K, Nishikimi T, Akimoto K, Ono H, Kangawa K, Matsuoka H. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats. J Hypertens. 2005 ;23:2287-96.

136. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006 ;69:318-28.

137. Hattori Y, Akimoto K, Nishikimi T, Matsuoka H, Kasai K. Activation of AMP-activated protein kinase enhances angiotensin ii-induced proliferation in cardiac fibroblasts. Hypertension. 2006 ;47:265-70.

138. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci. 2006;100:22-28.

139. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension. 2006;47:1075-83.

140. Nishikimi T. Editorial Comments : Do increased plasma adrenomedullin levels in

normotensive subjects precede hypertension?

J Hum Hypertens. 2006;20:557-9.

141. Nishikimi T, Mori Y, Ishimura K, Ishikawa Y, Koshikawa S, Tadokoro K, Akimoto K, Ono H, Kangawa K, Matsuoka H. Chronic effect of combined vasopeptidase inhibition and adrenomedullin in heart failure in rats. Am J Hypertension 2006;19:1039-1048
142. Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular Adiponectin Activates Nuclear Factor- κ B and Activating Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. Diabetes. 2007;56:804-8.
143. Caron K, Hagaman J, Nishikimi T, Kim HS, Smithies O. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci U S A. 2007;104:3420-
144. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, Ono H, Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens. 2007;25:1053-63.
145. Ikeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kawakami M, Momomura S, Saito M. N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. Regul Pept. 2007;141:154-8.
146. Watanabe K, Nishikimi T, Takamuro M, Yasuda K, Ishikawa Y, Tanabe S, Yamada O, Yagihara T, Suga S, Kangawa K, Matsuoka H, Echigo S. Possible role of adrenomedullin in the regulation of Fontan circulation: mature form of plasma adrenomedullin is extracted in the lung in patients with Fontan procedure. Regul Pept. 2007;141:129-34
147. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem. 2007;14:1689-99.
148. Nishikimi T, Minamino N, Horii K, Matsuoka H. Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32? Hypertension. 2007;50:e163.

149. Takemura N, Kono K, Tadokoro K, Shinbo G, Ito I, Abe C, Matsuhashi N, Iemura T, Nishikimi T, Horinaka S, Matsuoka H. Right atrial abnormalities in a patient with arrhythmogenic right ventricular cardiomyopathy without ventricular tachycardia. *J Cardiol.* 2008;51:205-9.
150. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. *J Hypertens.* 2008;26:1837-48.
151. Iemura-Inaba C, Nishikimi T, Akimoto K, Yoshihara F, Minamino N, Matsuoka H. Role of adrenomedullin system in lipid metabolism and its signaling mechanism in cultured adipocytes. *Am J Physiol Regul Integr Comp Physiol.* 2008;295:R1376-84.
152. Nishikimi T, Iemura-Inaba C, Akimoto K, Ishikawa K, Koshikawa S, Matsuoka H. Stimulatory and Inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) pathways in rat cultured adipocytes. *Regul Pept.* 2009;153:56-63.
153. Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. *Regul Pept.* 2009;154:45-53
154. Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, Yoshihara F, Nagaya N, Sakio H, Kangawa K, Matsuoka H. Effects of Long-Term Intravenous Administration of Adrenomedullin plus Human Atrial Natriuretic Peptide Therapy in Acute Decompensated Heart Failure: a pilot study *Circ J* 2009;73:892-898
155. Nishikimi T, Minamino N, Ikeda M, Takeda Y, Iemura-Inaba C, Ishimura K, Tadokoro K, Shibasaki I, Mochizuki Y, Fukuda H, Horiuchi Y, Oikawa O, Ieiri T, Matsubara M, Matsuoka M. Diversity of Molecular Forms of Plasma Brain Natriuretic Peptide in Heart failure –Different proBNP-108 to BNP-32 Ratios in Atrial and Ventricular Overload – Heart. 2010;96:432-9
156. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by

unilateral ureteral obstruction. Hypertens Res. 2010;33:965-73

157. Shibasaki I, Nishikimi T, Mochizuki Y, Yamada Y, Yoshitatsu M, Inoue Y, Kuwata T, Ogawa H, Tsuchiya G, Ishimitsu T, Fukuda H. Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease. Regul Pept. 2010;165:210-217
158. Hata L, Murakami M, Kuwahara K, Nakagawa Y, Kinoshita H, Usami S, Yasuno S, Fujiwara M, Kuwabara Y, Minami T, Yamada Y, Yamada C, Nakao K, Ueshima K, Nishikimi T, Nakao K. Zinc-finger protein 90 negatively regulates neuron-restrictive silencer factor-mediated transcriptional repression of fetal cardiac genes. J Mol Cell Cardiol. 2011;50:972-81.
159. Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y, Minamino N, Hirata Y, Mukoyama M, Nishikimi T, Nagai R. Japanese-Western consensus meeting on biomarkers. Int Heart J. 2011;52:253-65.
160. Nishikimi T, Minamino N, Nakao K. Diverse molecular forms of plasma B-type natriuretic peptide in heart failure. Curr Heart Fail Rep. 2011;8:140-6.
161. Nishikimi T, Nakao K, Kangawa K. Adrenomedullin in heart failure: Molecular mechanism and therapeutic implication. Current Hypertension Review 2011;7:273-283
162. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57:131-40.
163. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, Kinoshita H, Nakagawa Y, Kuwahara K, Nakao K. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart. 2012 Jan;98:152-61.
164. Kuwahara K, Nishikimi T, Nakao K. Transcriptional regulation of the fetal cardiac gene program. J Pharmacol Sci. 2012;119:198-203.

165. Nishikimi T. Do plasma levels of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) increase in diastolic dysfunction as well as in systolic dysfunction? *Circ J.* 2012;76:2540-1.
166. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, Kuwabara Y, Yamada Y, Yamada C, Shibata J, Usami S, Yasuno S, Nishikimi T, Ueshima K, Sata M, Nakano H, Seno T, Kawahito Y, Sobue K, Kimura A, Nagai R, Nakao K. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. *EMBO J.* 2012;31:4428-40.
167. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Minamino N, Nakao K. Complexity of molecular forms of B-type natriuretic peptide in heart failure. *Heart.* 2013;99:677-9.
168. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, Nakagawa Y, Kinoshita H, Yamada C, Nakao K, Minami T, Kuwabara Y, Kuwahara K, Masuda I, Kangawa K, Minamino N, Nakao K. Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. *PLoS One.* 2013;8:e53233.
169. Kuwabara Y, Kuwahara K, Takano M, Kinoshita H, Arai Y, Yasuno S, Nakagawa Y, Igata S, Usami S, Minami T, Yamada Y, Nakao K, Yamada C, Shibata J, Nishikimi T, Ueshima K, Nakao K. Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts. *J Am Heart Assoc.* 2013;2:e000150.
170. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Nakao K. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. *Curr Protein Pept Sci.* 2013;14:256-67.
171. Yasuno S, Kuwahara K, Kinoshita H, Yamada C, Nakagawa Y, Usami S, Kuwabara Y, Ueshima K, Harada M, Nishikimi T, Nakao K. Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy. *Br J Pharmacol.* 2013;170:1384-95.
172. Wetzel-Strong SE, Li M, Klein KR, Nishikimi T, Caron KM. Epicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis. *Dev Dyn.* 2014 ;243:243-56.

173. Nakagawa Y, Nishikimi T, Kuwahara K, Yasuno S, Kinoshita H, Kuwabara Y, Nakao K, Minami T, Yamada C, Ueshima K, Ikeda Y, Okamoto H, Horii K, Nagata K, Kangawa K, Minamino N, Nakao K. The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis. *PLoS One*. 2014;9:e92314.
174. Yamada Y, Kinoshita H, Kuwahara K, Nakagawa Y, Kuwabara Y, Minami T, Yamada C, Shibata J, Nakao K, Cho K, Arai Y, Yasuno S, Nishikimi T, Ueshima K, Kamakura S, Nishida M, Kiyonaka S, Mori Y, Kimura T, Kangawa K, Nakao K. Inhibition of N-type Ca²⁺ channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure. *Cardiovasc Res*. 2014;104:183-93.
175. Tomiyama H, Nishikimi T, Matsumoto C, Kimura K, Odaira M, Shiina K, Yamashina A. Longitudinal Changes in Late Systolic Cardiac Load and Serum NT-proBNP Levels in Healthy Middle-Aged Japanese Men. *Am J Hypertens*. 2015;28:452-8.
176. Nishikimi T, Nakagawa Y, Minamino N, Ikeda M, Tabei K, Fujishima A, Takayama K, Akimoto K, Yamada C, Nakao K, Minami T, Kuwabara Y, Kinoshita H, Tsutamoto T, Ishimitsu T, Kangawa K, Kuwahara K, Nakao K. Pro-B-type natriuretic peptide is cleaved intracellularly: impact of distance between O-glycosylation and cleavage sites. *Am J Physiol Regul Integr Comp Physiol*. 309:R639-49, 2015
177. Yamada C, Kuwahara K, Yamazaki M, Nakagawa Y, Nishikimi T, Kinoshita H, Kuwabara Y, Minami T, Yamada Y, Shibata J, Nakao K, Cho K, Arai Y, Honjo H, Kamiya K, Nakao K, Kimura T. The renin-angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischaemic cardiomyopathy. *Cardiovasc Res*. 109:162-73, 2016
178. Nakao K, Kuwahara K, Nishikimi T, Nakagawa Y, Kinoshita H, Minami T, Kuwabara Y, Yamada C, Yamada Y, Tokudome T, Nagai-Okatani C, Minamino N, Nakao YM, Yasuno S, Ueshima K, Sone M, Kimura T, Kangawa K, Nakao K. Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity. *Hypertension*. 69:286-296, 2017

179. Nakagawa Y, Nishikimi T, Kuwahara K, Fujishima A, Oka S, Tsutamoto T, Kinoshita H, Nakao K, Cho K, Inazumi H, Okamoto H, Nishida M, Kato T, Fukushima H, Yamashita JK, Wijnen WJ, Creemers EE, Kangawa K, Minamino N, Nakao K, Kimura T. MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts. *J Am Heart Assoc.* 6. pii: e003601, 2017
180. Kuwahara K, Nakagawa Y, Nishikimi T. Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance. *Circ J.* 2018;82:2455-2461.
181. Takahama H, Takashio S, Nishikimi T, Hayashi T, Nagai-Okatani C, Nakagawa Y, Amaki M, Ohara T, Hasegawa T, Sugano Y, Kanzaki H, Yasuda S, Kangawa K, Minamino N, Anzai T. Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure. *Int J Cardiol.* 2018;258:165-171.
182. Nishikimi T, Nakagawa Y. Adrenomedullin as a Biomarker of Heart Failure. *Heart Fail Clin.* 2018;14:49-55.
183. Nakagawa Y, Nishikimi T, Sakai H, Ohno S, Kinoshita H, Inazumi H, Moriuchi K, Kuwahara K, Horie M, Kimura T. Macro-pro-B-type natriuretic peptide (proBNP) and hidden macro-N-terminal proBNP: Case report. *Clin Biochem.* 2018;52:148-152.
184. Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. *Peptides.* 2019 ;111:18-25.
185. Nishikimi T, Nakagawa Y. Does impaired processing of proBNP cause decreased plasma BNP levels in obese heart failure patients? *Ann Translational Medicin* 2019 (in press)
186. Takashio S, Takahama H, Nishikimi T, Hayashi T, Nagai-Okatani C, Matsuo A, Nakagawa Y, Amano M, Hamatani Y, Okada A, Amaki M, Hasegawa T, Kanzaki H, Yasuda S, Kangawa K, Anzai T, Minamino N, Izumi C.: Superiority of pro-atrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: Comparison with B-type natriuretic peptide and other natriuretic peptide forms. *Open Heart*, 2019 (in press).

187. Takahama H, Nishikimi T, Takashio S, Hayashi T, Nagai-Okatani C, Asada T, Fujiwara A, Nakagawa Y, Amano M, Hamatani Y, Okada A, Amaki M, Hasegawa T, Kanzaki H, Nishimura K, Yasuda S, Kangawa K, Anzai T, Minamino N, Izumi C,: A change in the NT-proBNP/mature BNP molar ratio precedes worsening renal function in patients with acute heart failure: A novel predictor candidate for cardiorenal syndrome. JAHA 2019 (in press).
188. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Heart failure assessed based on plasma B-type natriuretic peptide (BNP) levels negatively impacts activity of daily living in patients with hip fracture. PLoS One. 2020;15:e0237387.
189. Horie K, Hossain MS, Kim Y, Akiko I, Kon R, Yamatsu A, Kishima M, Nishikimi T, Kim M. Effects of Banafine®, a fermented green banana-derived acidic glycoconjugate, on influenza vaccine antibody titer in elderly patients receiving gastrostomy tube feeding. J Food Sci. 2021; 86:1410-1417.
190. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Effect of heart failure and malnutrition, alone and in combination, on rehabilitation effectiveness in patients with hip fracture. Clin Nutr ESPEN. 2021;44:356-366.
191. Nishikimi T, Nakagawa Y. Potential pitfalls when interpreting plasma BNP levels in heart failure practice. J Cardiol. 2021;78:269-274.
192. Kimura A, Takahama H, Nishikimi T, Takashio S, Hayashi T, Nagai-Okatani C, Nakagawa Y, Yasuda S, Anzai T, Minamino N, Izumi C. Molecular ratio of mature B-type natriuretic peptide in acute heart failure: an indicator for ventricular contractile recovery. ESC Heart Fail. 2021 (in press)
doi: 10.1002/ehf2.13684.

錦見俊雄 業績

論文(邦文)

1. 奥久雄、錦見俊雄、村井佳代子、安田光隆、寺柿政和、小松祐司、木積一憲、吉村隆喜、生野喜康、竹内一秀、田中忠治郎、武田忠直. 左室短軸3断面による左室駆出分画算出の試み: 日超医論文集、1984、44、53-54
2. 安田光隆、奥久雄、広田一仁、梶野宏美、錦見俊雄、瓦林孝彦、村井佳代子、吉村隆喜、竹内一秀、武田忠直. Ioproterenol 負荷時の高血圧心の心機能: J.Cardiography、1985、15、761-771
3. 寺柿政和、板金広、広田一仁、錦見俊雄、瓦林孝彦、安田光隆、村井佳代子、秋岡要、吉村隆喜、奥久雄、竹内一秀、武田忠直. 術前後の心機能を評価し得た褐色細胞腫の一症例: 日超医論文集、1985、46、205-206
4. 村井佳代子、広田一仁、西上宏美、錦見俊雄、瓦林孝彦、寺柿政和、秋岡要、安田光隆、吉村隆喜、奥久雄、竹内一秀、武田忠直. 第4音を有する狭心症の拡張能の検討: 日超医論文集、1985、46、205-206
5. 錦見俊雄、板金広、広田一仁、瓦林孝彦、村井佳代子、秋岡要、寺柿政和、安田光隆、吉村隆喜、奥久雄、竹内一秀、武田忠直. 心膜中皮腫2例の超音波所見: 日超医論文集、1985、47、504-505
6. 蒼山稔、広田一仁、錦見俊雄、瓦林孝彦、村井佳代子、安田光隆、秋岡要、寺柿政和、奥久雄、竹内一秀、武田忠直. 高齢者バルサルバ洞破裂の一例: 日超医論文集、1986、49、711-712
7. 広田一仁、生野喜康、錦見俊雄、瓦林孝彦、村井佳代子、安田光隆、奥久雄、竹内一秀、武田忠直. 因子分析とフーリエ解析による局所壁運動異常診断能の比較: J.Cardiography、1986、16、319-329
8. 錦見俊雄、河野雅和、栗原直嗣、横山広之、井関敏之. 若年健康人の運動に伴う心房性利尿ペプチドの動態と各種ホルモンの関係: 厚生省科研費報告書、1986、44-51

- 9.武田忠直、竹内一秀、瓦林孝彦、村井佳代子、錦見俊雄、広田一仁、酒井宏純、寺柿政和.
BAYe9736(Nimoldipine)錠の単回ならびに連続投与試験:薬理と治療、1987、15、119-130
- 10.河野雅和、秋岡要、村川浩一、錦見俊雄、安成憲一、横川晃治、寺柿政和、松浦敏文、栗原直嗣、安田光隆、奥久雄、竹内一秀、武田忠直. Ca拮抗薬と心房性利尿ペプチド:薬理と治療、1987、15(suppl)、187-193
- 11.切池信夫、前田泰久、泉屋洋一、西脇新一、片原節、な井弘二、川北幸男、錦見俊雄、竹内一秀、武田忠直. Thioridazine 投与中に Torsades de Pointes を呈した一例:精神医学、1987、29、301-309
- 12.錦見俊雄、広田一仁、酒井宏純、葭山稔、村井佳代子、秋岡要、寺柿政和、安田光隆、奥久雄、竹内一秀、武田忠直. 二次元血流映像法により診断された冠動脈痙攣の2例:日超医論文集、1987、50、151-152
- 13.板金広、岡本泰之、飯田英隆、成子隆彦、酒井宏純、錦見俊雄、よし山稔、村井佳代子、寺柿政和、秋岡要、安田光隆、奥久雄、竹内一秀、武田忠直. 左室右房交通症、大動脈弁閉鎖不全症に感染性心内膜炎を合併しバルサルバ洞穿孔をきたした一例:日超医論文集、1987、51、621-622
- 14.武田忠直、錦見俊雄、河野雅和. 運動負荷とANPL:肺と心、1987、34、324-327
- 15.秋岡要、河野雅和、錦見俊雄、寺柿政和、安田光隆、奥久雄、竹内一秀、武田忠直. 本態性高血圧患者における運動負荷時の血行動態および血漿中心房性Na利尿ペプチド濃度に及ぼすNisoldipineの影響:基礎と臨床、1988、52、1465-1467
- 16.安田光隆、奥久雄、錦見俊雄、村井佳代子、秋岡要、寺柿政和、竹内一秀、武田忠直、井上英二、生野善康. 心尖部肥大型心筋症における拡張障害の局在性:J.Cardiography、1988、18、105-112
- 17.葭山稔、金勝慶、山岸広之、大村崇、谷知子、柳志郎、錦見俊雄、戸田為久、寺柿政和、秋岡要、竹内一秀、武田忠直. 虚血心筋障害における心筋組織ACEの役割、心筋の構造と代謝、15、1993、149-153

- 18.錦見俊雄、松岡博昭. 最近の循環器新薬の使い方と問題点 高圧薬高脂血漿薬:循環科学、15、1995:340-343
- 19.石光俊彦、錦見俊雄、斎藤能彦、北村和雄、松岡博昭、寒川賢治、松尾壽之、尾前照雄. 各種循環器疾患における血漿アドレノメデュリン濃度と他の循環調節ホルモンとの関係. 心臓 27、suppl 2、1995
- 20.錦見俊雄. アドレノメデュリンの臨床研究:循環器病研究の進歩X VI、1995、33-39
- 21.錦見俊雄、吉原史樹、森本淳詞、石川一彦、吉富雄二、石光俊彦、松岡博昭、尾前照雄、斎藤能彦、寒川賢治、松尾壽之. 本態性高血圧における血漿 ANP、BNP 濃度測定の意義:心臓 28、1996:197-202
- 22.錦見俊雄、吉見宏樹. 高血圧性心不全: 別冊日本臨床 領域別症候群シリーズ、循環 器症候群I、42-45
- 23.吉見宏樹 、錦見俊雄. 心不全『急性心不全、慢性心不全;左心不全、右心不全;収縮期不全、拡張期不全;高拍出性心不全、低拍出性心不全』別冊日本臨床 領域別症 候群シリーズ、循環器症候群I、107-109
- 24.石光俊彦、錦見俊雄、南順一、河野雄平、松岡博昭、寒川賢治、松尾壽之. 本態性高血圧における急性、慢性の食塩負荷に対する交感神経、内分泌系の反応:心臓28巻、suppl 4.80-84、1996
- 25.錦見俊雄 . アドレノメデュリンと循環器疾患:現代医療 28、No11:121-124,1996
- 26.石川一彦、錦見俊雄、吉原史樹、石光俊彦、河野雄平、吉見宏樹、瀧下修一、斎藤能彦、寒川賢治、松尾壽之. 降圧療法に伴って著しい血漿 ANP,BNP,Adrenomedullin 値の低下左室肥大の退縮をみた悪性高血圧の一例:Therapeutic Research. Vol.17: No10: 26-28, 1996
- 27.錦見俊雄. 腎血管性高血圧とは:Medical Technology 臨時増刊 Vol 25, No 5, 429-435、1997

- 28.錦見俊雄. 心不全における循環ペプチドの病態 - 生理学的意義と心不全治療への応用:進歩する心臓研究、1997、X V II巻、8号、68-82
- 29.錦見俊雄, 寒川賢治. アドレノメデュリン:臨床検査 1997; Vol41: No 7: 826-828
- 30.錦見俊雄. 肥大心における ANP, BNP の意義: THERAPEUTIC RESEARCH、1997 vol. 18 suppl. 3 Symposium Series No. 599, page7-9
- 31.錦見俊雄. 心肥大における ANP,BNP の意義:Modern Physician Vol.17、 1997、953-957
- 32.錦見俊雄. アドレノメデュリンと心不全:Heart View 1997 ;Vol 1: No 8: 56-61
- 33.錦見俊雄. アドレノメデュリンの循環器疾患における病態生理的意義:医学の歩み Vol 184, No.1, 1998, 64-69
- 34.錦見俊雄. 血漿 ANP, BNP 濃度と循環器疾患 :Medical Technology ;Vol 26; 1998 No1:105-106
- 35.錦見俊雄. 21世紀カンファ - 血漿 ANP、BNP と循環器疾患:THERAPEUTIC RESEARCH 1998, Vol 19, no.6, 195-202
- 36.錦見俊雄, 寒川賢治. Adrenomedullin と循環調節機構:Cardiologist Vol3 ; No.5:319-325, 1998
- 37.錦見俊雄. 私の処方-高血圧緊急症-:Modern Physician Vol.18、1998、334
- 38.錦見俊雄. 心疾患におけるアドレノメデュリンの変化とその意義:Molecular Medicine, Vol.35、1998、1022-1032
- 39.錦見俊雄. 心肥大と ANP, BNP—その臨床的意義:Progress in Medicine 1998; 10: 28-33
- 40.錦見俊雄. アドレノメデュリンの循環器疾患における病態生理的意義の解明と治療への応用:研究助成業績報告集、1997、Page 39-42、財団法人循環器病研究振興財団編

41. 中尾一和、斎藤能彦、薦本尚慶、錦見俊雄. 新しい循環ホルモンの臨床応用—ナトリウム利尿ペプチド系アドレノメデュリンを中心に:循環科学 Vol.18、1998、1144-1158
42. 錦見俊雄. アドレノメデュリンによる循環調節—高血圧症との関連—:医学の歩み Vol.189, 1999, 542-546
43. 堀尾武史、錦見俊雄、吉原史樹、松尾壽之、瀧下修一、寒川賢治. 内因性心房性 Na 利尿ペプチドによる培養心筋細胞肥大抑制作用:血圧 Vol. 7, 28-32, 1999
43. 錦見俊雄. 心不全におけるアドレノメデュリンの病態生理的意義:Cardiac Practice Vol.10、1999、79-87
44. 木全心一、宮内卓、錦見俊雄、吉村道博. 座談会『心不全と循環ペプチド』:Cardiac Practice Vol.10、1999、111-128
45. 錦見 俊雄、堀尾 武史、神本 有美、吉原 史樹 、稻永 隆、河野 雄平、瀧下 修一、寒川 賢治. 高血圧患者の血中および尿中 Adrenomedullin-Mature(AM-M; 活性型)と AM-Gly(非活性型)の病態生理学的意義 THERAPEUTIC RESEARCH Vol.20、1999、34-37
46. 錦見 俊雄. データブック 血栓症の大規模臨床試験 動脈硬化危険因子-1
低用量アスピリンによる心血管予防効果に関する男性医師対象の無作為化比較二 重盲検試験. 血栓と循環 Vol. 7, 1999, 145-146
47. 錦見俊雄, 寒川賢治. Adrenomedullin と本態性高血圧
日本臨床 増刊号 高血圧上巻 Vol. 58 IV.本態性高血圧症-成因と病態生理 アドレノメデュリン 481-486, 2000
48. 錦見俊雄、松岡博昭. 日本臨床 増刊号 高血圧上巻 Vol. 58 V.本態性高 血圧症-臨床 血圧変動因子 ビタミン 690-693 , 2000
49. 錦見俊雄、松岡博昭. 症例に学ぶ高血圧治療専門医のみるポイント49、2000, MEDICAL VIEW 社(片山茂裕、後藤淳朗、島田和幸)
腎血管性高血圧の治療指針 page 126-127

50. 錦見俊雄、松岡博昭. 臨床検査診断マニュアル(永井書店)-古澤新平他編 集 2000
8. 心機能 a.心房性ナトリウム利尿ペプチド(ANP)、脳性ナトリウム 利尿ペプチド(BNP)、page 678-681、サイクリック GMP(cGMP) page 682、エンドセリン page 683-684
- 51.錦見俊雄 軽症高血圧 最新医学社 Vol 4, No.3, page 12-13 2000
- 52.錦見俊雄 神経体液性因子と高血圧性左室肥大 Heart View 2000 ;Vol 4 : No 9: page 48-54
53. 鈴木武志、南順一、矢部彰久、轟政勝、植竹修一郎、渡辺滋子、原すおみ、坪光雄介、八木博、浅川洋、小野英彦、沼部敦司、堀中繁夫、錦見俊雄、石光俊彦、本田幹彦、吉田謙一郎、松岡博昭 腹腔鏡下で摘出が可能であった褐色細胞腫の1例 血圧 Vol.7, 83-87, 2000
- 54.錦見俊雄 Urocortin ホルモンと臨床 Vol.49, 17-22, 2001
- 55.Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension J Cardiol. 2001 ;37:110-1. Japanese.
56. 錦見俊雄、松岡博昭 アドレノメデュリンと高血圧症 循環器科 Vol.49, 491-497, 2001
57. 錦見 俊雄. 内蔵内蔵反射 viscero-visceral reflex、大動脈体反射 aortic body reflex、頸動脈小体 carotid body、頸動脈体反射 carotid body reflex、ベインブリッジ反射 bainbridge reflex、
看護医学大辞典. 和田 攻、南裕子小峰光博総集編、医学書院(東京)2002
58. 錦見俊雄 高血圧性心肥大と心臓内分泌代謝 血圧 Vol.9, 57-62, 2002
59. 高橋正樹、玉野宏一、原すおみ、小林学、本多勇晴、植竹修一朗、水戸部利恵子、
錦見俊雄、松岡博昭 多発性の左室憩室に second harmonic imaging が有用であった1症例
The Circulation Frontier 4巻、57-61, 2002
60. 錦見俊雄 血漿BNP値モニタ一下での心不全治療 Medical Practice 2002

61. 錦見俊雄 ANP, BNP 測定の意義とその解釈 検査と技術 Vol.30, 561-563, 2002
62. 錦見俊雄 ナトリウム利尿ペプチドを生かした心不全の診断／治療の最前線
—脳性利尿ペプチド(BNP)の心不全診断薬への応用— 医薬ジャーナル斎藤能彦編 page
44-51, 2003
63. 錦見俊雄 若手研究者による最新海外情報 『生活習慣病に対する分子遺伝学的アプローチ』 血管 Vol.26, 73-75 , 2003
64. 錦見俊雄 NSAID と腎機能障害 Medical Practice One Point Advice 2004, Vol 21,
page 142
65. 錦見俊雄 アドレノメデュリンと本態性高血圧症 日本臨床 2004;62 Suppl 9:260-3
66. 錦見俊雄 ウロテンシンIIと心疾患 日本臨床 2004;62 Suppl 9:722-6
67. 錦見俊雄：ナトリウム利尿ペプチドを利用した左室肥大の診断と治療効果の判定:高血圧診療のコツと落とし穴. 島田和幸編, 中山書店, pp.26-27
- 68.錦見俊雄 THERAPEUTIC RESEARCH Vol.25、2004、1102(Comment)
THERAPEUTIC RESEARCH Vol.25、2004、1115(Comment)
69. 錦見俊雄,、松岡博昭:8. 心機能(a)心房性ナトリウム利尿ペプチド(ANP)、脳性利尿ペプチド(BNP)、臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.678-682, 2004.
70. 錦見俊雄、松岡博昭:8. 心機能(d)サイクリック GMP、臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.683, 2004.
71. 錦見俊雄、松岡博昭:8. 心機能(e)エンドセリン(ET)、臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.684, 2004.
72. 錦見俊雄 心肥大をともなう高血圧:選択薬剤と降圧目標 EBMジャーナル 2005

73. 錦見俊雄 新 BNP と日常診療－心機能異常の早期発見のために－(BNP と生活習慣病)
pp.123-138、2005
74. 錦見俊雄、松岡博昭 高血圧による臓器障害のメカニズム Molecular Medicine 臨時増刊号
2005;42;244-250
75. 錦見俊雄 アドレノメデュリンと高血圧、腎疾患 分子血管病 2005;62;51-56
76. 錦見俊雄 JSH2004 ガイドラインの検証 臓器障害を合併する高血圧の治療 メビオ
2005 ;Vol 22 : No 7: page 38-45
77. 錦見俊雄 高血圧性心肥大は降圧薬で退縮可能か、その選択薬剤は？
EBM 循環器疾患の治療 2006-2007、三田村秀男、山科明、川名正敏、桑島巖編著、中外医学社、
page.442-445、2005.
78. 錦見俊雄、松岡博昭 神経体液性因子を基盤とした心不全治療
日本臨床生理学会誌 Vol 35 : No 4: page 199-205、2005
79. 座談会 下条文武、伊藤貞嘉、倉林正彦、代田浩之、錦見俊雄 心腎連関におけるARB の
役割 新薬と臨床 Vol 54 : No 9: page 37-47、2005
80. 小林直彦、錦見俊雄、松岡博昭 Dahl ラットと心不全 Vol 64:S5:303-310 日本臨床
81. 錦見俊雄 心不全を有する高血圧例の降圧薬の使用法 メビオ Vol 23 : No 4: page
51-57、2006
82. 錦見俊雄 第35回日本心脈管作動物質学会学会 血圧 Vol 134 : No 4: page 82-83、
2006
83. 錦見俊雄、松岡博昭 高血圧性糸球体硬化に対する Rho-kinase 阻害薬の腎保護作用と
その分子機序 脈管学 46:667-673,2006
84. 錦見俊雄、松岡博昭 循環生理活性物質の血圧調節に関する分子機序と病態生理的意

85. 錦見俊雄 高血圧性糸球体硬化進展における Rho/Rho-kinase 系の役割
- Rho-kinase 阻害薬の糸球体保護効果とその分子機序 - 日本薬理学会誌 Vol 128, 153-159, 2006
86. 錦見俊雄、松岡博昭 ARB+ACE 阻害薬 日本臨床 心不全下巻 65, suppl 5, 140-144, 2007
87. 錦見俊雄. Plenary session 3 ISH ハイライト 2007, p127-p130
88. 錦見俊雄、松岡博昭. 高脂血症への介入による脳血管障害の再発予防 老年医学 Vol 44, 1675-1678, 2006
89. 錦見俊雄. III-3-② 合併症のある場合、心脈管疾患、これだけは知っておきたい日常診療のポイント 高齢者高血圧、松岡博昭編、54-63、医薬ジャーナル社、東京、2006
90. 錦見俊雄、III-3-④ 合併症のある場合、代謝性疾患、これだけは知っておきたい日常診療のポイント 高齢者高血圧、松岡博昭編、70-76、医薬ジャーナル社、東京、2006
91. 錦見俊雄. 高血圧診療マニュアル
心筋梗塞、狭心症、心筋症、大動脈瘤、高脂血症、高血圧性緊急症
92. 錦見俊雄. 心不全マーカーとしての BNP の意義 日本医事新報 Vol 4324, 122-123, 2007
93. 錦見俊雄 心不全患者の血圧管理 血圧 Vol 14 : page 36-40, 2007
94. 錦見 俊雄. 最新の心不全薬物療法 栃木病院薬剤師会誌 Vol 72, 19-21, 2007
95. 南順一、小林直彦、錦見俊雄、松岡博昭. 第17回ヨーロッパ高血圧学会(ESH) 血圧 Vol 14 : page 92-93, 2007
96. 錦見俊雄 循環器疾患における Adrenomedullin の意義と臨床応用 血圧 Vol 15, 68-73, 2008

97. 小林直彦、錦見俊雄 Dahl 心不全モデルラット 日本臨床 67, 569-577, 2009
98. 錦見俊雄、循環器領域への新しい遺伝子改変マウス作成技術の応用 日本臨床 67, 685-689, 2009
99. 錦見俊雄. 心血管病の診断と治療におけるバイオマーカーの有用性-BNP - メビオ 26,24-32, 2009
100. 村上礼子、鈴木美津恵、鹿村真理子、錦見俊雄 地域生活を継続している慢性心不全患者のセルフケアー外来患者のセルフケア影響因子に注目して一 獨協医科大学看護学部紀要 3, 1-10, 2010
101. 錦見俊雄. 分子標的薬と高血圧・循環器疾患
日本臨床. ;68:1911-6, 2010
102. 錦見俊雄. BNP, ANP と高血圧. 血圧 vol. 19 :42-47. 2012
103. 錦見俊雄. 心疾患のバイオマーカーとしての BNP の臨床的意義—基礎的・臨床的視点から一 日本臨床 70: 774-784, 2012.
104. 錦見俊雄. 降圧薬としてのエンドセリン拮抗薬、PDE5阻害薬 —治療抵抗性高血圧におけるエンドセリン拮抗薬、PDE5阻害薬の可能性—
循環器内科 72, 515-520, 2012
105. 錦見俊雄. B 型ナトリウム利尿ペプチド(BNP)分子型の最新知見—BNP の生化学、分子生物学、臨床的意義を含めて—. シーメンス サイエンティフィック インフォメーション、2:1-11, 2013
106. 錦見俊雄. ストローマからみた心血管病 ストローマとナトリウム利尿ペプチド—急性心筋梗塞の病態生理的意義と臨床応用— 循環器内科. 74:174-180, 2013
107. 南野直人、錦見俊雄, 中川靖章、寒川賢治. BNP の多様な分子型の分別測定による心不全診断法の革新. 循環器病研究の進歩 XXXV :58-67, 2014

108. 錦見俊雄、南野直人. Na 利尿ペプチドの発見と薬理作用. Fluid Management Renaissance 4:43-49, 2014
109. 錦見 俊雄 先生. BNP 検査で潜在性心不全を診るー生活習慣病における BNP 検査の有用性ー. シーメンス サイエンティフィック インフォメーション、2:1-11, 2015
110. 錦見俊雄. 分子標的薬と高血圧・循環器疾患. 腎臓内科・泌尿器科、4: 82-89, 2016
111. 錦見俊雄,中川靖章. 心不全における血中 BNP 分子型の多様性とその意義:proBNP, BNP [1-32]関連分子種, nonglycosylated-NT-BNP, glycosylated-NT-BNP について. 循環器内科、79: 510-516, 2016
112. 錦見俊雄. 現場からの発現(正論・異論)循環器内科から見た超高齢化社会. 老人医療 NEWS 142: 2, 2016
113. 錦見俊雄、松浦道子. 重症例にもあきらめない、粘り強いリハビリで在宅復帰を目指す—わかくさ竜間リハビリテーション病院における取り組み—慢性期リハビリテーション学会誌 JMC113 号 63-67, 2017
114. 錦見俊雄. 回復期リハビリテーション病棟における BNP 検査の有用性ー 医療経済的、病院経営的意義の考察を含めて ー. シーメンス サイエンティフィック インフォメーション、2:1-7, 2018
115. Special Talk. 斎藤能彦、錦見俊雄、佐藤幸人, 土田桂蔵. 2025 年医療制度改革における BNP 検査の重要性. MMJ 14, 66-71, 2018
116. 錦見俊雄. 心不全診療におけるB N P 解釈のピットフォール —B N P値を過大評価もしくは過小評価する病態— Heart View 23:28-36;2019
117. 錦見俊雄. アンジオテンシン受容体・ネプリライシン阻害薬(ARNI)と BNP, NT-proBNP の関係とは? 循環器内科 89:1-6 , 2021
118. 杉田智加、錦見俊雄. ポリファーマシーはリハビリテーションの治療効果を減弱するのか?

—脳血管疾患患者での検討— リハビリナース14:70-74 , 2021